Abstract
Five long-acting (LA) antiretrovirals (ARVs) are currently available in a limited number of countries worldwide for HIV-1 prevention or treatment—cabotegravir, rilpivirine, lenacapavir, ibalizumab, and dapivirine. Implementing use of LA ARVs into routine clinical practice requires significant changes to the current framework of HIV-1 prevention, treatment, and service provision. Given the novelty, complexity, and interdisciplinary requirements needed to safely and optimally utilize LA ARVs, consensus recommendations on the use of LA ARVs will assist clinicians in optimizing use of these agents. The purpose of these recommendations is to provide guidance for the clinical use of LA ARVs for HIV-1 treatment and prevention. In addition, future areas of research are also identified and discussed.
Original language | English (US) |
---|---|
Pages (from-to) | 494-538 |
Number of pages | 45 |
Journal | Pharmacotherapy |
Volume | 44 |
Issue number | 7 |
DOIs | |
State | Published - Jul 2024 |
Bibliographical note
Publisher Copyright:© 2024 The Authors. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy published by Wiley Periodicals LLC on behalf of Pharmacotherapy Publications, Inc.
Keywords
- antiretrovirals
- HIV
- long acting
- pre-exposure prophylaxis
- prevention
- treatment
PubMed: MeSH publication types
- Journal Article
- Practice Guideline